Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214688 · ClinicalTrials.gov registry record · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
A Phase 2 study of Allogeneic Stem Cell Transplant Recipient, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
- 3
- Study locations
NCT07214688 is a Phase 2 study of Allogeneic Stem Cell Transplant Recipient that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 209 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT07214688, a Phase 2 study of Allogeneic Stem Cell Transplant Recipient, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
- 3
- Study locations
Study Summary
The Flu-TBI 800 trial is a prospective, single-arm, multicenter, interventional phase 2 study to evaluate whether fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide (PTCy) (experimental regimen) improves the 1-year survival of allogeneic stem cell transplant recipients.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil (MMF)
- RADIATION Intermediate-dose Total Body Irradiation (TBI)
- DRUG Post-transplant Cyclophosphamide (PTCy)
Study Locations (3)
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
- John Theurer Cancer Center at Jersey Shore University Medical Center - Neptune City
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2026-01-06 |
| Est. Completion | 2032-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07214688
The ClinicalTrials.gov registry entry for NCT07214688 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allogeneic Stem Cell Transplant Recipient appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT07214688 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT07214688 about?
NCT07214688 is a clinical study titled "Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies". The Flu-TBI 800 trial is a prospective, single-arm, multicenter, interventional phase 2 study to evaluate whether fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide (PTCy) (experimental regimen) improves the 1-year survival of allogeneic ste...
What is the current status of trial NCT07214688?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2026-01-06. Estimated completion is 2032-01.
What conditions does trial NCT07214688 study?
This clinical trial studies the following conditions: Allogeneic Stem Cell Transplant Recipient.
What interventions are being tested in trial NCT07214688?
The interventions under investigation include: Fludarabine (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (MMF) (DRUG), Intermediate-dose Total Body Irradiation (TBI) (RADIATION), Post-transplant Cyclophosphamide (PTCy) (DRUG).
Who is sponsoring clinical trial NCT07214688?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214688 being conducted?
This trial has 3 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Stem Cell Transplant Recipient
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.